---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-046489"
form_type: "8-K"
ticker: "BFRG"
cik: "0001829247"
company_name: "BullFrog AI Holdings, Inc."
filed_at: "2023-12-29T23:59:59+00:00"
generated_at: "2026-06-07T06:01:58.532975+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bullfrog AI highlights 2023 achievements: $8.4M IPO, first revenue, key partnerships

## Summary
- Completed $8.4M IPO listing on Nasdaq in 2023; maintained low burn rate quarter to quarter.
- Recorded first earned revenue in Q3 2023; transition to commercial operations.
- Entered exclusive partnership with Lieber Institute for Brain Development for neuropsychiatric drug discovery.
- Demonstrated efficacy of oncology drug candidates BF-223 and BF-222 in glioblastoma animal model; patent issued for BF-223.
- Identified three novel colorectal cancer targets via JCVI partnership; market $11.5B in 2022.

## SEC filing metadata
- accession: 0001493152-23-046489
- form_type: 8-K
- ticker: BFRG
- cik: 0001829247
- company_name: BullFrog AI Holdings, Inc.
- filed_at: 2023-12-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829247/000149315223046489/0001493152-23-046489-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829247/000149315223046489/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-046489
- JSON: https://secwatch.observer/filing/0001493152-23-046489.json
- Plain text: https://secwatch.observer/filing/0001493152-23-046489.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.